Additionally, we saw increased expense in research, development, and medical affairs associated with product improvements, new day study costs, and travel related to increased engagement with clinicians.

Nov 14, 2022 / receipt, needs a key / Phil, CFO | earnings call 2022-11-14 | transcript b78d0e93-51f7-4dc6-a127-0155523d318c | chars 11755-11958 | segment 12

It's similar to, frankly, what we saw a year or two ago when COVID first started is we cut back on all the travel spending from all of our reps in the U.S. and really engaged the doctors more remotely because even if we were out there trying to get in the clinics, they did not have the patient flows there.

May 9, 2022 / receipt, needs a key / Rick Hysworth, CEO | earnings call 2022-05-09 | transcript f652011a-d203-4776-8cf5-559bd0abfbd1 | chars 26045-26352 | segment 26

And, again, just as we get back into the mode of travel and everything, just understand that there will be more of those normal items that return as well, such as travel within Europe and some of the other places that have been stymied to some degree by the pandemic.

Feb 24, 2022 / receipt, needs a key / Rick Eisworth, other | earnings call 2022-02-24 | transcript 713764aa-556a-4f0a-aae4-3c53bc9e51f2 | chars 22107-22374 | segment 22